{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T02:36:22Z","timestamp":1791426982752,"version":"4.3.3"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T00:00:00Z","timestamp":1783728000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100014588","name":"Sanofi Pasteur SA","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014588","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.ejpb.2026.115177","type":"journal-article","created":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T23:24:34Z","timestamp":1783725874000},"page":"115177","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Formulation and stability design spaces for a new yellow fever vaccine"],"prefix":"10.1016","volume":"227","author":[{"given":"Didier","family":"Cl\u00e9net","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-5189-9325","authenticated-orcid":false,"given":"No\u00e9mie","family":"Mansois","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yawen","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruna Araujo","family":"Dos Ramos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Landry","family":"Bertaux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Vangelisti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejpb.2026.115177_b0005","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.jcv.2014.08.030","article-title":"Yellow fever","volume":"64","author":"Monath","year":"2015","journal-title":"Journal of Clinical Virology"},{"key":"10.1016\/j.ejpb.2026.115177_b0010","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1517\/14712598.8.11.1787","article-title":"Yellow fever vaccine: past, present and future","volume":"8","author":"Roukens","year":"2008","journal-title":"Expert Opinion on Biological Therapy"},{"key":"10.1016\/j.ejpb.2026.115177_b0015","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1586\/erv.12.6","article-title":"Review of the risks and benefits of yellow fever vaccination including some new analyses","volume":"11","author":"Monath","year":"2012","journal-title":"Expert Review of Vaccines"},{"key":"10.1016\/j.ejpb.2026.115177_b0020","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1006\/biol.1997.0056","article-title":"Yellow Fever Vaccines","volume":"25","author":"Barrett","year":"1997","journal-title":"Biologicals"},{"key":"10.1016\/j.ejpb.2026.115177_b0025","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1084\/jem.65.6.767","article-title":"THE EFFECT OF PROLONGED CULTIVATION IN VITRO UPON THE PATHOGENICITY OF YELLOW FEVER VIRUS","volume":"65","author":"Theiler","year":"1937","journal-title":"Journal of Experimental Medicine"},{"key":"10.1016\/j.ejpb.2026.115177_b0030","doi-asserted-by":"crossref","first-page":"2941","DOI":"10.1016\/j.vaccine.2006.06.082","article-title":"High stability of yellow fever 17D-204 vaccine: A 12-year restrospective analysis of large-scale production","volume":"25","author":"Barban","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.ejpb.2026.115177_b0035","doi-asserted-by":"crossref","first-page":"e76","DOI":"10.1097\/INF.0000000000002625","article-title":"Yellow Fever Vaccination In EGG-Allergic Children","volume":"39","author":"Sharma","year":"2020","journal-title":"Pediatric Infectious Disease Journal"},{"key":"10.1016\/j.ejpb.2026.115177_b0040","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1016\/S1473-3099(24)00406-7","article-title":"Safety and immunogenicity of a next-generation live-attenuated yellow fever vaccine produced in a Vero cell line in the USA: a phase 1 randomised, observer-blind, active-controlled, dose-ranging clinical trial","volume":"24","author":"Modjarrad","year":"2024","journal-title":"The Lancet Infectious Diseases"},{"key":"10.1016\/j.ejpb.2026.115177_b0045","unstructured":"World Health Organization (WHO), Guidelines on the Stability Evaluation of Vaccines for Use under Extended Controlled Temperature Conditions, Annex 5, TRS No 999; World Health Organization, (2016). https:\/\/cdn.who.int\/media\/docs\/default-source\/biologicals\/vaccine-standardization\/ectc\/guidelines-on-ectc-trs_999_a5.pdf?sfvrsn=aae8a045_5&download=true (accessed April 2, 2026)."},{"key":"10.1016\/j.ejpb.2026.115177_b0050","unstructured":"World Health Organization (WHO), Vaccine Vial Monitor-WHO\/PQS\/E06\/IN05.2, (2006). https:\/\/extranet.who.int\/prequal\/sites\/default\/files\/document_files\/WHO_PQS_E06_IN05_2.pdf (accessed April 2, 2026)."},{"key":"10.1016\/j.ejpb.2026.115177_b0055","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.ejpb.2019.07.008","article-title":"A spray freeze dried micropellet based formulation proof-of-concept for a yellow fever vaccine candidate","volume":"142","author":"Cl\u00e9net","year":"2019","journal-title":"European Journal of Pharmaceutics and Biopharmaceutics"},{"key":"10.1016\/j.ejpb.2026.115177_b0060","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1016\/j.vaccine.2021.02.033","article-title":"Next generation live-attenuated yellow fever vaccine candidate: Safety and immuno-efficacy in small animal models","volume":"39","author":"Piras-Douce","year":"2021","journal-title":"Vaccine"},{"key":"10.1016\/j.ejpb.2026.115177_b0065","unstructured":"JMP, (n.d.). https:\/\/www.jmp.com\/en\/software (accessed April 2, 2026)."},{"key":"10.1016\/j.ejpb.2026.115177_b0070","article-title":"SmartChemistry brings the power of AI and machine learning into your lab","author":"Houlton","year":"2023","journal-title":"Chemistry World"},{"key":"10.1016\/j.ejpb.2026.115177_b0075","unstructured":"S. Lundberg, S.-I. Lee, A Unified Approach to Interpreting Model Predictions, (2017). https:\/\/doi.org\/10.48550\/ARXIV.1705.07874."},{"key":"10.1016\/j.ejpb.2026.115177_b0080","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.tca.2014.01.005","article-title":"Prediction of thermal stability of materials by modified kinetic and model selection approaches based on limited amount of experimental points","volume":"579","author":"Roduit","year":"2014","journal-title":"Thermochimica Acta"},{"key":"10.1016\/j.ejpb.2026.115177_b0085","doi-asserted-by":"crossref","first-page":"27","DOI":"10.18609\/vac.2025.054","article-title":"Predicting stability of conventional and mRNA-based vaccines","volume":"4","author":"Scaccia","year":"2025","journal-title":"Vaccine Insights"},{"key":"10.1016\/j.ejpb.2026.115177_b0090","unstructured":"AKTS-Thermokinetics, (n.d.). https:\/\/www.akts.com\/ (accessed January 13, 2026)."},{"key":"10.1016\/j.ejpb.2026.115177_b0095","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1586\/14760584.2014.923761","article-title":"Tools and approaches to ensure quality of vaccines throughout the cold chain","volume":"13","author":"Kartoglu","year":"2014","journal-title":"Expert Review of Vaccines"},{"key":"10.1016\/j.ejpb.2026.115177_b0100","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1016\/j.vaccine.2014.01.038","article-title":"Benefits of using vaccines out of the cold chain: Delivering Meningitis A vaccine in a controlled temperature chain during the mass immunization campaign in Benin","volume":"32","author":"Zipursky","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.ejpb.2026.115177_b0105","article-title":"Bayesian optimization and machine learning for vaccine formulation development","volume":"20","author":"Li","year":"2025","journal-title":"PLoS One"},{"key":"10.1016\/j.ejpb.2026.115177_b0110","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1080\/10837450701212826","article-title":"Effect of Cations and Anions on Glass Transition Temperatures in Excipient Solutions","volume":"12","author":"Nesarikar","year":"2007","journal-title":"Pharmaceutical Development and Technology"},{"key":"10.1016\/j.ejpb.2026.115177_b0115","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1016\/j.vaccine.2009.11.024","article-title":"Heat-stable measles vaccine produced by spray drying","volume":"28","author":"Ohtake","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.ejpb.2026.115177_b0120","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.ejpb.2016.04.010","article-title":"Spectroscopic evaluation of a freeze-dried vaccine during an accelerated stability study","volume":"104","author":"Hansen","year":"2016","journal-title":"European Journal of Pharmaceutics and Biopharmaceutics"},{"key":"10.1016\/j.ejpb.2026.115177_b0125","doi-asserted-by":"crossref","first-page":"3055","DOI":"10.1002\/jps.24117","article-title":"Advanced Kinetic Analysis as a Tool for Formulation Development and Prediction of Vaccine Stability","volume":"103","author":"Cl\u00e9net","year":"2014","journal-title":"Journal of Pharmaceutical Sciences"},{"key":"10.1016\/j.ejpb.2026.115177_b0130","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1016\/j.xphs.2018.04.019","article-title":"Urea Improves Stability of Inactivated Polio Vaccine Serotype 3 During Lyophilization and Storage in Dried Formulations","volume":"107","author":"Qi","year":"2018","journal-title":"Journal of Pharmaceutical Sciences"},{"key":"10.1016\/j.ejpb.2026.115177_b0135","doi-asserted-by":"crossref","first-page":"163","DOI":"10.2217\/imt.10.108","article-title":"L -Proline-Stabilized Human IgG: Privigen\u00ae 10% for Intravenous Use and Hizentra\u00ae 20% for Subcutaneous Use","volume":"3","author":"Berger","year":"2011","journal-title":"Immunotherapy"},{"key":"10.1016\/j.ejpb.2026.115177_b0140","unstructured":"Alfa-chemistry, Proline: An Essential Stabilizer in Vaccine Development, (n.d.). https:\/\/vaccinelab.alfa-chemistry.com\/proline-an-essential-stabilizer-in-vaccine-development.html (accessed June 16, 2026)."},{"key":"10.1016\/j.ejpb.2026.115177_b0145","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.ejpb.2011.09.014","article-title":"Design space approach in the optimization of the spray-drying process","volume":"80","author":"Lebrun","year":"2012","journal-title":"European Journal of Pharmaceutics and Biopharmaceutics"},{"key":"10.1016\/j.ejpb.2026.115177_b0150","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1080\/10543406.2013.834922","article-title":"A Bayesian Design Space for Analytical Methods Based on Multivariate Models and Predictions","volume":"23","author":"Lebrun","year":"2013","journal-title":"Journal of Biopharmaceutical Statistics"},{"key":"10.1016\/j.ejpb.2026.115177_b0155","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1080\/10543400802278197","article-title":"A Bayesian Approach to the ICH Q8 Definition of Design Space","volume":"18","author":"Peterson","year":"2008","journal-title":"Journal of Biopharmaceutical Statistics"},{"key":"10.1016\/j.ejpb.2026.115177_b0160","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1002\/jlcr.3613","article-title":"NOTA\u2010PRGD2 and NODAGA\u2010PRGD2\u00a0: Bioconjugation, characterization, radiolabelling, and design space","volume":"61","author":"Salv\u00e9","year":"2018","journal-title":"Labelled Comp Radiopharmac"},{"key":"10.1016\/j.ejpb.2026.115177_b0165","doi-asserted-by":"crossref","unstructured":"A.D. Ergin, B. Uner, Quality by Design for Parenteral Formulations, in: N.K. Jain, N. Bajwa (Eds.), Introduction to Quality by Design (QbD), Springer Nature Singapore, Singapore, 2024: pp. 217\u2013242. https:\/\/doi.org\/10.1007\/978-981-99-8034-5_9.","DOI":"10.1007\/978-981-99-8034-5_9"},{"key":"10.1016\/j.ejpb.2026.115177_b0170","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1208\/s12248-014-9598-3","article-title":"Understanding Pharmaceutical Quality by Design","volume":"16","author":"Yu","year":"2014","journal-title":"AAPS J"},{"key":"10.1016\/j.ejpb.2026.115177_b0175","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2026.115781","article-title":"Artificial intelligence and machine learning guided optimization in drug delivery","author":"Ros","year":"2026","journal-title":"Advanced Drug Delivery Reviews"},{"key":"10.1016\/j.ejpb.2026.115177_b0180","unstructured":"EMA, Final Report from the FDA-EMA pilot program for the parallel assessment of quality-by-design elements of marketing applications - EMA\/213746\/2017, (2017). https:\/\/www.fda.gov\/media\/104371\/download."},{"key":"10.1016\/j.ejpb.2026.115177_b0185","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2022.115149","article-title":"Application of design space and quality by design methodologies combined with ultra high-performance liquid chromatography for the optimization of the sample preparation of complex pharmaceutical dosage forms","volume":"227","author":"Yogendrarajah","year":"2023","journal-title":"Journal of Pharmaceutical and Biomedical Analysis"},{"key":"10.1016\/j.ejpb.2026.115177_b0190","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.trac.2012.09.007","article-title":"Design Spaces for analytical methods","volume":"42","author":"Rozet","year":"2013","journal-title":"TrAC Trends in Analytical Chemistry"},{"key":"10.1016\/j.ejpb.2026.115177_b0195","doi-asserted-by":"crossref","first-page":"10077","DOI":"10.1038\/s41598-023-35870-6","article-title":"A universal tool for stability predictions of biotherapeutics, vaccines and in vitro diagnostic products","volume":"13","author":"Huelsmeyer","year":"2023","journal-title":"Sci Rep"},{"key":"10.1016\/j.ejpb.2026.115177_b0200","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.3390\/vaccines9101114","article-title":"Use of Stability Modeling to Support Accelerated Vaccine Development and Supply","volume":"9","author":"Campa","year":"2021","journal-title":"Vaccines"},{"key":"10.1016\/j.ejpb.2026.115177_b0205","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2021.121143","article-title":"Predictive modeling for assessing the long-term thermal stability of a new fully-liquid quadrivalent meningococcal tetanus toxoid conjugated vaccine","volume":"609","author":"Neyra","year":"2021","journal-title":"International Journal of Pharmaceutics"},{"key":"10.1016\/j.ejpb.2026.115177_b0210","doi-asserted-by":"crossref","first-page":"4673","DOI":"10.1021\/acs.molpharmaceut.4c00609","article-title":"Predicting the Long-Term Stability of Biologics with Short-Term Data","volume":"21","author":"Dillon","year":"2024","journal-title":"Mol. Pharmaceutics"},{"key":"10.1016\/j.ejpb.2026.115177_b0215","doi-asserted-by":"crossref","DOI":"10.1016\/j.xphs.2025.103873","article-title":"Predictive stability in biopharmaceuticals and vaccines: Perspectives and recommendations towards accelerating patient access","author":"Skomski","year":"2025","journal-title":"Journal of Pharmaceutical Sciences 114"},{"key":"10.1016\/j.ejpb.2026.115177_b0220","doi-asserted-by":"crossref","first-page":"3503","DOI":"10.1007\/BF03037892","article-title":"Transformation of austenite at constant subcritical temperatures","volume":"1","author":"Davenport","year":"1970","journal-title":"Metall Trans"},{"key":"10.1016\/j.ejpb.2026.115177_b0225","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1002\/adfm.201000377","article-title":"Time\u2013Temperature\u2013Transformation (TTT) Diagrams for Crystallization of Metal Oxide Thin Films","volume":"20","author":"Rupp","year":"2010","journal-title":"Adv Funct Materials"},{"key":"10.1016\/j.ejpb.2026.115177_b0230","unstructured":"WHO, World Health Organization, Requirements for yellow fever vaccine, Expert committee on biological standardization, Requirements for yellow fever vaccine. Expert committee on biological standardization, technical report series 46th Report. Genova. 840: annex2, (1998). https:\/\/cdn.who.int\/media\/docs\/default-source\/biologicals\/vaccine-quality\/requirements-for-yellow-fever-vaccine-annex-29df8ed2a-f690-4ed0-8f19-e0e10b850513.pdf?sfvrsn=d41319c9_1&download=true."},{"key":"10.1016\/j.ejpb.2026.115177_b0235","doi-asserted-by":"crossref","first-page":"281","DOI":"10.18609\/vac.2022.040","article-title":"Stability assessment for vaccines: recent trends & learnings from accelerated scenarios","volume":"01","author":"Campa","year":"2022","journal-title":"Vaccine Insights"},{"key":"10.1016\/j.ejpb.2026.115177_b0240","doi-asserted-by":"crossref","first-page":"735","DOI":"10.5731\/pdajpst.2024.012976","article-title":"Case Studies on Changes and Proposed Process Development Approaches Reflecting Applicability of PDA Technical Report No. 89: Strategies for Vaccine Development and Lifecycle Management","volume":"78","author":"Campa","year":"2024","journal-title":"PDA Journal of Pharmaceutical Science and Technology"},{"key":"10.1016\/j.ejpb.2026.115177_b0245","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.3390\/molecules24122217","article-title":"Continuous Monitoring of Shelf Lives of Materials by Application of Data Loggers with Implemented Kinetic Parameters","volume":"24","author":"Roduit","year":"2019","journal-title":"Molecules"},{"key":"10.1016\/j.ejpb.2026.115177_b0250","unstructured":"EMA, ICH Q1 Guideline on stability testing of drug substances and drug products_Step 2b - EMA\/CHMP\/ICH\/130561\/2025, (2025). https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/draft-ich-q1-guideline-stability-testing-drug-substances-drug-products-step-2b_en.pdf."}],"container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641126001980?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641126001980?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T11:17:13Z","timestamp":1788175033000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0939641126001980"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":50,"alternative-id":["S0939641126001980"],"URL":"https:\/\/doi.org\/10.1016\/j.ejpb.2026.115177","relation":{},"ISSN":["0939-6411"],"issn-type":[{"value":"0939-6411","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Formulation and stability design spaces for a new yellow fever vaccine","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutics and Biopharmaceutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejpb.2026.115177","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 sanofi. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"115177"}}